Decision on the commencement of review of available strategic options
Current Report No 31/2020
Legal basis: Article 17(1) of MAR – inside information
The Management Board of Medicalgorithmics S.A. (“Company”) hereby informs that on 11 August 2021 decided to commence the review of the strategic options available to the Company supporting the further development of the operations of the capital group of the Company (the “Group”).
The review of strategic options is aimed at identifying possible directions of development of the Group’s operations, and, consequently, the selection of the most advantageous way to achieve the long-term goal of the Group, which is to ensure the best possible position of the Group on the market of advanced systems for cardiology and to maximize value for the Company’s shareholders.
The Management Board of the Company will analyze various strategic options in all areas of the Group’s business activities, including considering acquiring a strategic or financial investor, entering into a strategic alliance, entering into a transaction with a different structure, as well as the lack of the above-mentioned activities.
The Management Board of the Company will commence selection of consultants that will support the Company in the strategic options review process. The communication consultant of the Company in the area of the strategic options review is CC Group Sp. z o.o., with Piotr Owdziej, Investor Relations Manager as a contact person, e-mail address: firstname.lastname@example.org.
At the same time, the Management Board of the Company informs that so far it has not made any decisions related to the selection of a specific strategic option and allows for the possibility that, after the review, no available strategic option will be selected. The Issuer will publish information on the course of the review process in accordance with applicable law.